公开(公告)号：US09243247B2

公开(公告)日：2016-01-26

申请号：US14122236

申请日：2012-05-24

Applicant: Suk Kyeong Lee ,  Hoyun Choi

Inventor： Suk Kyeong Lee ,  Hoyun Choi

IPC: A61K48/00 ,  C12N15/113 ,  A61K31/713 ,  A61K45/06

CPC classification number: C12N15/113 ,  A61K31/713 ,  A61K45/06 ,  C12N2310/141 ,  A61K2300/00

Abstract: Provided is a use of an miRNA of an Epstein-Barr virus (EBV), more specifically, EBV miR-BART4-5p, miR-BART4-3p, miR-BART1-5p, miR-BART15-3p, miR-BART5-5p, miR-BART5-3p, miR-BART16-5p, miR-BART16-3p, miR-BART17-3p, miR-BART21-3p, miR-BART18-5p, miR-BART7-5p, miR-BART9-5p, miR-BART22-5p, miR-BART20-3p, miR-BART13-5p, miR-BART13-3p, miR-BART2-3p, and mimics thereof for promoting apoptosis or inhibiting cell growth.

Abstract translation: 提供了EB病毒（EBV）的miRNA，更具体地，EBV miR-BART4-5p，miR-BART4-3p，miR-BART1-5p，miR-BART15-3p，miR-BART5-5p ，miR-BART5-3p，miR-BART16-5p，miR-BART16-3p，miR-BART17-3p，miR-BART21-3p，miR-BART18-5p，miR-BART7-5p，miR-BART9-5p，miR -BART22-5p，miR-BART20-3p，miR-BART13-5p，miR-BART13-3p，miR-BART2-3p及其模拟物，用于促进细胞凋亡或抑制细胞生长。

公开(公告)号：US09180138B2

公开(公告)日：2015-11-10

申请号：US13437676

申请日：2012-04-02

Applicant: Raymond F. Schinazi ,  Dennis C. Liotta ,  Chung K. Chu ,  J. Jeffrey McAtee ,  Junxing Shi ,  Yongseok Choi ,  Kyeong Lee ,  Joon H. Hong

Inventor： Raymond F. Schinazi ,  Dennis C. Liotta ,  Chung K. Chu ,  J. Jeffrey McAtee ,  Junxing Shi ,  Yongseok Choi ,  Kyeong Lee ,  Joon H. Hong

IPC: A01N61/00 ,  A61K48/00 ,  A61K31/708 ,  C07D405/04 ,  C07D473/00 ,  C07H19/06 ,  C07H19/10 ,  C07H19/16 ,  A61K31/706 ,  A61K31/7064 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  C07H1/00 ,  C07G3/00

CPC classification number: A61K31/7076 ,  A61K31/706 ,  A61K31/7064 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/708 ,  C07D405/04 ,  C07D473/00 ,  C07H19/06 ,  C07H19/10 ,  C07H19/16

Abstract: 2′-Fluoro-nucleoside compounds are disclosed which are useful in the treatment of hepatitis B infection, hepatitis C infection, HIV and abnormal cellular proliferation, including tumors and cancer. The compounds have the general formulae: wherein Base is a purine or pyrimidine base; R1 is OH, H, OR3, N3, CN, halogen, CF3, lower alkyl, amino, loweralkylamino, di(lower)alkylamino, or alkoxy; R2 is H, phosphate, or a stabilized phosphate prodrug; acyl, or other pharmaceutically acceptable leaving benzyl, a lipid, an amino acid, peptide, or cholesterol; and R3 is acyl, alkyl, phosphate, or other pharmaceutically acceptable leaving group; or a pharmaceutically acceptable salt thereof.

Abstract translation: 公开了可用于治疗乙型肝炎感染，丙型肝炎感染，HIV和异常细胞增殖（包括肿瘤和癌症）的2'-氟 - 核苷化合物。 所述化合物具有以下通式：其中碱是嘌呤或嘧啶碱; R 1是OH，H，OR 3，N 3，CN，卤素，CF 3，低级烷基，氨基，低级烷基氨基，二（低级）烷基氨基或烷氧基; R2是H，磷酸盐或稳定的磷酸盐前药; 酰基或其它药学上可接受的苄基，脂质，氨基酸，肽或胆固醇; 烷基，磷酸酯或其它药学上可接受的离去基团; 或其药学上可接受的盐。

公开(公告)号：US08940936B2

公开(公告)日：2015-01-27

申请号：US13880642

申请日：2011-10-17

Applicant: Kyeong Lee ,  Mi Sun Won ,  Hwan Mook Kim ,  Song Kyu Park ,  Kiho Lee ,  Ki Hoon Lee ,  Chang Woo Lee ,  Jung Joon Lee ,  Kyung Sook Chung ,  Bo Kyung Kim ,  Yinglan Jin ,  Seung-hee Lee

Inventor： Kyeong Lee ,  Mi Sun Won ,  Hwan Mook Kim ,  Song Kyu Park ,  Kiho Lee ,  Ki Hoon Lee ,  Chang Woo Lee ,  Jung Joon Lee ,  Kyung Sook Chung ,  Bo Kyung Kim ,  Yinglan Jin ,  Seung-hee Lee

IPC: C07C233/07 ,  A61K31/167 ,  C07C235/28 ,  C07C311/16 ,  C07D295/088

CPC classification number: A61K31/5375 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/14 ,  A61K9/20 ,  A61K9/48 ,  A61K31/167 ,  A61K31/196 ,  A61K31/24 ,  A61K31/34 ,  A61K31/40 ,  A61K31/417 ,  A61K31/4409 ,  C07C233/07 ,  C07C235/28 ,  C07C311/16 ,  C07C311/46 ,  C07C317/40 ,  C07C2603/74 ,  C07D295/088

Abstract: The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis. Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.

Abstract translation: 本发明涉及抑制HF-1活性的化合物，其制备方法以及含有该化合物作为活性成分的药物组合物。 本发明的化合物通过非选择性细胞毒性表现出抗癌活性，但通过抑制HIF-1的活性，该转录因子在癌细胞生长和转移中起重要作用。 因此，根据本发明的化合物或其药学上可接受的盐抑制HIF-1活性，因此可以用作结肠癌，肝癌，胃癌和乳腺癌等实体瘤的治疗剂。 此外，根据本发明的化合物或其药学上可接受的盐可以用作用于糖尿病性视网膜病变或关节炎的治疗剂的活性成分，当HIF-1的缺氧诱导的VEGF表达增加时，可能变差。

公开(公告)号：US08563197B2

公开(公告)日：2013-10-22

申请号：US12238884

申请日：2008-09-26

Applicant: Sung-soo Suh ,  Suk-joo Lee ,  Yong-hee Park ,  Mi-kyeong Lee

Inventor： Sung-soo Suh ,  Suk-joo Lee ,  Yong-hee Park ,  Mi-kyeong Lee

IPC: G06F17/50

CPC classification number: G03F1/36

Abstract: Design rules for circuit patterns of a semiconductor device are identified, and schematic layouts of the circuit patterns are generated according to the design rules. Lithography friendly layout (LFL) circuit patterns are generated from the schematic layouts. Target layout circuit patterns are generated from the LFL circuit patterns. Optical proximity effect correction (OPC) is performed on the target layout circuit patterns to generate OPC circuit patterns. A mask is fabricated from the OPC circuit patterns, and may be used fabricate a semiconductor device.

Abstract translation: 识别半导体器件的电路图案的设计规则，根据设计规则生成电路图案的原理图布局。 从原理图布局生成光刻友好布局（LFL）电路图案。 目标布局电路图案是从LFL电路图形生成的。 对目标布局电路图案执行光学邻近效应校正（OPC）以产生OPC电路图案。 掩模由OPC电路图形制成，可用于制造半导体器件。

公开(公告)号：US20130237542A1

公开(公告)日：2013-09-12

申请号：US13880642

申请日：2011-10-17

Applicant: Kyeong Lee ,  Mi Sun Won ,  Hwan Mook Kim ,  Song Kyu Park ,  Kiho Lee ,  Ki Hoon Lee ,  Chang Woo Lee ,  Jung Joon Lee ,  Kyung Sook Chung ,  Bo Kyung Kim ,  Yinglan Jin ,  Seung-hee Lee

Inventor： Kyeong Lee ,  Mi Sun Won ,  Hwan Mook Kim ,  Song Kyu Park ,  Kiho Lee ,  Ki Hoon Lee ,  Chang Woo Lee ,  Jung Joon Lee ,  Kyung Sook Chung ,  Bo Kyung Kim ,  Yinglan Jin ,  Seung-hee Lee

IPC: C07C235/28 ,  C07D295/088 ,  C07C311/16

CPC classification number: A61K31/5375 ,  A61K9/0019 ,  A61K9/08 ,  A61K9/14 ,  A61K9/20 ,  A61K9/48 ,  A61K31/167 ,  A61K31/196 ,  A61K31/24 ,  A61K31/34 ,  A61K31/40 ,  A61K31/417 ,  A61K31/4409 ,  C07C233/07 ,  C07C235/28 ,  C07C311/16 ,  C07C311/46 ,  C07C317/40 ,  C07C2603/74 ,  C07D295/088

Abstract: The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis. Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.

Abstract translation: 本发明涉及抑制HF-1活性的化合物，其制备方法以及含有该化合物作为活性成分的药物组合物。 本发明的化合物通过非选择性细胞毒性表现出抗癌活性，但通过抑制HIF-1的活性，该转录因子在癌细胞生长和转移中起重要作用。 因此，根据本发明的化合物或其药学上可接受的盐抑制HIF-1活性，因此可以用作结肠癌，肝癌，胃癌和乳腺癌等实体瘤的治疗剂。 此外，根据本发明的化合物或其药学上可接受的盐可以用作用于糖尿病性视网膜病变或关节炎的治疗剂的活性成分，当HIF-1的缺氧诱导的VEGF表达增加时，可能变差。

公开(公告)号：US20110125324A1

公开(公告)日：2011-05-26

申请号：US12949923

申请日：2010-11-19

Applicant: Sanghoon BAEK ,  Jeongsuk Yoon ,  Seungmin Baek ,  Sangik Na ,  Kwangro Joo ,  Tae-Kyeong Lee ,  Se-Young Oh ,  Donghoon Yi ,  Taegon Park

Inventor： Sanghoon BAEK ,  Jeongsuk Yoon ,  Seungmin Baek ,  Sangik Na ,  Kwangro Joo ,  Tae-Kyeong Lee ,  Se-Young Oh ,  Donghoon Yi ,  Taegon Park

IPC: G05B15/00 ,  G06F19/00

CPC classification number: G05D1/0274 ,  A47L2201/04 ,  G05B2219/40435 ,  G05D1/0219 ,  G05D1/0227 ,  G05D1/0242 ,  G05D1/0255 ,  G05D1/027 ,  G05D1/0272 ,  G05D2201/0203 ,  G05D2201/0215

Abstract: A robot cleaner and a method of controlling a robot cleaner are provided. The robot cleaner is capable of automatically compensating for and adjusting a moving angle and a position using an appropriate sensor and control algorithm while performing a cleaning operation in a relatively large space. This may reduce a position error, allow a cleaning region to be effectively identified as a region to be cleaned or a region having already been cleaned, thus improving cleaning performance and efficiency.

Abstract translation: 提供机器人清洁器和控制机器人清洁器的方法。 机器人清洁器能够在相对大的空间中执行清洁操作时，使用适当的传感器和控制算法自动补偿和调整移动角度和位置。 这可以减少位置误差，允许将清洁区域有效地识别为要清洁的区域或已经被清洁的区域，从而提高清洁性能和效率。

公开(公告)号：USD616400S1

公开(公告)日：2010-05-25

申请号：US29328798

申请日：2008-12-02

Applicant: Yong Ho Lee ,  Hee Su Yang ,  Yoon Kyeong Lee ,  Young Hun Jang ,  Sung Gu Joe

Designer： Yong Ho Lee ,  Hee Su Yang ,  Yoon Kyeong Lee ,  Young Hun Jang ,  Sung Gu Joe

公开(公告)号：US20090306078A1

公开(公告)日：2009-12-10

申请号：US12306319

申请日：2007-07-03

Applicant: Jung Joon Lee ,  Jeong-Hyung Lee ,  Kyeong Lee ,  Young-Soo Hong ,  B.K. Shanthaveerappa ,  Yinlan Jin ,  Jin Hwan Kim ,  Xuejun Jin

Inventor： Jung Joon Lee ,  Jeong-Hyung Lee ,  Kyeong Lee ,  Young-Soo Hong ,  B.K. Shanthaveerappa ,  Yinlan Jin ,  Jin Hwan Kim ,  Xuejun Jin

IPC: A61K31/5377 ,  C07C233/33 ,  A61K31/167 ,  A61K31/41 ,  C07D257/04 ,  C07D295/15 ,  A61K31/423 ,  C07D263/57 ,  A61P19/02

CPC classification number: C07C237/42 ,  C07C235/24 ,  C07C255/60 ,  C07C271/42 ,  C07C307/02 ,  C07C311/46 ,  C07C317/40 ,  C07C2603/74 ,  C07D213/38 ,  C07D213/75 ,  C07D213/79 ,  C07D213/80 ,  C07D213/81 ,  C07D235/12 ,  C07D257/04 ,  C07D263/56 ,  C07D307/52 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D413/12

Abstract: Disclosed herein are an HIF-1 inhibitor, a method for the preparation thereof, and a pharmaceutical composition comprising the same as an active ingredient. The HIF-1 inhibitor shows anticancer activity thanks to the inhibition activity against HIF-1, a transcription factor which plays an important role in the growth and metastasis of cancer, but not to general cytotoxicity. Thus, the HIF-inhibitor and a pharmaceutically acceptable salt thereof can be used as a therapeutic for various cancers such as liver cancer; stomach cancer and breast cancer. Also, the compound having inhibition activity against HIF-1 is useful in the treatment of diabetic retinopathy and arthritis, which are aggravated by HIF-1-mediated VEGF expression.

Abstract translation: 本文公开了HIF-1抑制剂，其制备方法和包含其作为活性成分的药物组合物。 HIF-1抑制剂由于对HIF-1的抑制活性而显示出抗癌活性，HIF-1是在癌症的生长和转移中起重要作用的转录因子，而不是一般的细胞毒性。 因此，HIF抑制剂及其药学上可接受的盐可以用作各种癌症如肝癌的治疗剂; 胃癌和乳腺癌。 此外，对HIF-1具有抑制活性的化合物可用于治疗由HIF-1介导的VEGF表达而恶化的糖尿病性视网膜病变和关节炎。

公开(公告)号：US07582501B2

公开(公告)日：2009-09-01

申请号：US11724982

申请日：2007-03-15

Applicant: Jae-Kyeong Lee ,  Kwan-Tack Lim

Inventor： Jae-Kyeong Lee ,  Kwan-Tack Lim

IPC: H01L21/00 ,  H01L31/036 ,  H01L31/112

CPC classification number: H01L27/124

Abstract: A TFT array panel having signal lines of low resistivity is presented. The TFT array panel includes a substrate; a gate line including a gate electrode formed on the substrate and having a single-layered structure; a gate insulating layer formed on the gate line; a semiconductor layer formed on the gate insulating layer; a barrier layer formed on the semiconductor layer and including nitrogen; a data line including a source electrode formed on the barrier layer and having a single-layered structure; a drain electrode formed on the barrier layer, spaced apart from the source electrode and having a single-layered structure; and a pixel electrode electrically connected to the drain electrode. The TFT array panel may include contact holes extending to the end portions of the gate line, the data line, and the drain electrode, and molybdenum or molybdenum alloy buffer members in the contact holes.

Abstract translation: 提出了具有低电阻率信号线的TFT阵列面板。 TFT阵列面板包括基板; 栅线，包括形成在所述基板上并具有单层结构的栅电极; 栅极绝缘层，形成在栅极线上; 形成在所述栅极绝缘层上的半导体层; 形成在所述半导体层上并包含氮的阻挡层; 数据线，包括形成在所述阻挡层上并具有单层结构的源电极; 漏电极，形成在阻挡层上，与源电极间隔开并具有单层结构; 以及电连接到漏电极的像素电极。 TFT阵列面板可以包括延伸到栅极线，数据线和漏电极的端部的接触孔，以及接触孔中的钼或钼合金缓冲构件。

公开(公告)号：US20090181050A1

公开(公告)日：2009-07-16

申请号：US12407445

申请日：2009-03-19

Applicant: Kyu-wan Kim ,  Hyi-jeong Ji ,  Youn-kyeong Lee ,  Wan-kyu Kim ,  Hee-ku Lee ,  Won-kyum Kim

Inventor： Kyu-wan Kim ,  Hyi-jeong Ji ,  Youn-kyeong Lee ,  Wan-kyu Kim ,  Hee-ku Lee ,  Won-kyum Kim

IPC: A61K39/116 ,  A61P31/04

CPC classification number: A61K39/0017 ,  A61K39/0018 ,  A61K39/05 ,  A61K39/08 ,  A61K39/099 ,  A61K39/12 ,  A61K2039/521 ,  A61K2039/55505 ,  A61K2039/70 ,  C12N2730/10134

Abstract: The present invention relates to a method for manufacturing a combined vaccine capable of concurrently preventing multiple diseases such as diphtheria, tetanus, pertussis, and hepatitis B which should be prevented in an infant. The method for manufacturing a combined vaccine according to the present invention includes the steps of independently adsorbing each protective antigen to an adsorbent of a aluminum hydroxide gel with respect to various diseases such as diphtheria, tetanus, pertussis, and hepatitis B which should be prevented in the infants, and combining each protective antigen adsorbed to the adsorbent after the adsorption. In the present invention, it is possible to concurrently prevent multiple diseases such as diphtheria, tetanus, pertussis, and hepatitis B which should be prevented in the infant using a combined vaccine manufactured according to the present invention.

Abstract translation: 本发明涉及一种能够同时预防婴儿应预防多发性疾病如白喉，破伤风，百日咳和乙型肝炎的组合疫苗的制造方法。 根据本发明的组合疫苗的制备方法包括以下步骤：针对各种疾病如白喉，破伤风，百日咳和乙型肝炎，独立地将每种保护性抗原吸附到氢氧化铝凝胶的吸附剂上，这些疾病应当被防止 并且吸附后吸附到吸附剂上的每种保护性抗原结合在一起。 在本发明中，可以使用根据本发明制造的组合疫苗同时预防在婴儿中应该预防多种疾病如白喉，破伤风，百日咳和乙型肝炎。